NOV
13

GRANT OF AWARD SHARES UNDER THE SHARE AWARD SCHEME

OCT
26

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 26 OCTOBER 2023

OCT
10

NOTICE OF ADJOURNED EXTRAORDINARY GENERAL MEETING

OCT
08

TYPHOON ARRANGEMENT FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON 9 OCTOBER 2023

SEP
26

Interim dividend for six months ended 30 June 2023

SEP
26

FDA APPROVAL OF IND FOR UBT251 INJECTION

SEP
21

Interim dividend for six months ended 30 June 2023

SEP
21

PAYMENT OF 2023 INTERIM DIVIDEND

SEP
19

INSIDE INFORMATION PLACING OF SHARES BY CONTROLLING SHAREHOLDER

SEP
14

NOTICE OF EXTRAORDINARY GENERAL MEETING

SEP
13

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ADOPTION OF THE AMENDED AND RESTATED ARTICLES OF ASSOCIATION

SEP
08

APPROVAL FOR CLINICAL TRIAL OF THE GROUP'S PRODUCT TUL01101 TABLETS

SEP
08

APPROVAL FOR CLINICAL TRIAL OF UBT251 INJECTION ON INDICATION OF NON-ALCOHOLIC FATTY LIVER DISEASE

SEP
06

UPDATED INFORMATION ON THE GROUP'S PRODUCT IBUPROFEN SUSTAINED-RELEASE CAPSULES

SEP
06

UPDATED INFORMATION OF THE GROUP'S PRODUCTS - MEROPENEM FOR INJECTION

SEP
03

APPROVAL FOR CLINICAL TRIAL OF UBT251 INJECTION ON INDICATION OF OVERWEIGHT OR OBESITY

AUG
30

Interim dividend for six months ended 30 June 2023

AUG
29

Interim Results Announcement For the six months ended 30 June 2023

AUG
29

APPROVED FOR CLINICAL TRIAL OF THE GROUP'S PRODUCT UBT251 INJECTION

AUG
23

UPDATED INFORMATION ON THE GROUP'S PRODUCT LIRAGLUTIDE INJECTION

AUG
17

DATE OF BOARD MEETING

AUG
16

POSITIVE PROFIT ALERT

AUG
04

PROPOSED ADOPTION OF THE 2023 SHARE AWARD SCHEME

JUL
26

UPDATED INFORMATION ON THE GROUP'S PRODUCT PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM FOR INJECTION

JUL
03

Special dividend for the year ended 31 December 2022

JUL
03

Final dividend for the year ended 31 December 2022

JUL
03

PAYMENT OF 2022 FINAL DIVIDEND AND SPECIAL DIVIDEND

JUL
02

List of Directors and Their Role and Function

JUL
02

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN THE COMPOSITION OF BOARD COMMITTEES

JUN
23

POLL RESULTS OF THE 2023 ANNUAL GENERAL MEETING

JUN
16

UPDATED INFORMATION ON THE GROUP'S PRODUCT UBT251 INJECTION

APR
27

NOTICE OF ANNUAL GENERAL MEETING

APR
19

UPDATED INFORMATION ON THE GROUP'S PRODUCT

APR
14

UPDATED INFORMATION ON THE GROUP'S PRODUCT

MAR
31

List of Directors and Their Role and Function

MAR
31

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

MAR
27

Special dividend for the year ended 31 December 2022

MAR
23

Special dividend for the year ended 31 December 2022

MAR
23

Final dividend for the year ended 31 December 2022

MAR
22

2022 ANNUAL RESULTS ANNOUNCEMENT

MAR
14

POSITIVE PROFIT ALERT

MAR
08

DATE OF BOARD MEETING

MAR
03

UPDATED INFORMATION ON THE GROUP'S PRODUCT TUL12101 EYE DROPS